Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 5/20 | 0.42 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.41 |
| ▸ | METAP1 | P53582 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 6/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048715 | 0.74 | METAP1 (0.58) | PDE5AHPSEMETAP1METAP2AURKA | |
| SCHEMBL1170747 | 0.66 | METAP1 (0.72) | PDE5AHPSEMETAP1METAP2AURKA | |
| SCHEMBL24112427 | 0.64 | NUDT1 (0.53) | PDE5AHPSEMETAP1METAP2AURKA | |
| SCHEMBL14115825 | 0.63 | METAP1 (0.49) | PDE5AHPSEMETAP1METAP2AURKA | |
| SCHEMBL27593194 | 0.62 | ALDH1A1 (0.49) | PDE5AHPSEPRMT5KMT2A | |
| SCHEMBL14022276 | 0.62 | HPSE (0.65) | PDE5AHPSEAURKAPRMT5 | |
| SCHEMBL14115848 | 0.62 | AURKA (0.62) | PDE5AHPSEMETAP1METAP2AURKA | |
| SCHEMBL10432840 | 0.62 | PDE5A (0.43) | PDE5AHPSEMETAP1METAP2AURKA | |
| SCHEMBL10432837 | 0.62 | HPSE (0.43) | PDE5AHPSEMETAP1METAP2AURKA | |
| SCHEMBL27787407 | 0.62 | METAP1 (0.66) | PDE5AHPSEMETAP1METAP2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1250337-B1 | SUBSTITUTED HOMOPIPERIDINYL BENZIMIDAZOLE ANALOGUES AS FUNDIC RELAXANTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-03 | — | — | EP | disclosed |
| US-7304052-B2 | Substituted homopiperidinyl benzimidazole analogues as fundic relaxants | JANSSEN PHARMACEUITCA N.V. (BE) | 2007-12-04 | — | — | US | disclosed |
| US-20030139393-A1 | Substituted homopiperidinyl benzimidazole analogues as fundic relaxants | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-07-24 | — | — | US | disclosed |
| EP-1250337-A1 | SUBSTITUTED HOMOPIPERIDINYL BENZIMIDAZOLE ANALOGUES AS FUNDIC RELAXANTS | Janssen Pharmaceutica N.V. (BE) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001046189-A1 | SUBSTITUTED HOMOPIPERIDINYL BENZIMIDAZOLE ANALOGUES AS FUNDIC RELAXANTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139393-A1 | Substituted homopiperidinyl benzimidazole analogues as fundic relaxants | HRH2, CBR1, HTR1D | PDE5A 447/4885HPSE 4345/4885METAP1 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.